Selley Ryan S, Portney Daniel A, Lawton Cort D, Shockley Michael D, Christian Robert A, Saltzman Matthew D, Hsu Wellington K
Orthopedics. 2019 Nov 1;42(6):349-354. doi: 10.3928/01477447-20190906-07. Epub 2019 Sep 12.
There are conflicting reports regarding the efficacy of Major League Baseball (MLB) pitchers following medial ulnar collateral ligament reconstruction (UCLR). As advanced baseball metrics have revolutionized the way general managers define pitchers' value, the authors believe that these should be used to measure clinical outcomes after UCLR. All MLB pitchers who underwent UCLR from April 1, 1991, through July 1, 2016, were compiled (N=253). Pitcher demographics and statistics were collected for up to 3 full seasons preceding and following surgery. Data for pitching controls (all MLB [AMLB] pitchers) were also collected (N=14,756). Prior to surgery, pitchers with UCLR were significantly better than the AMLB pitchers in nearly all advanced value-based statistics: higher wins above replacement (WAR; 0.93 vs 0.78; 95% confidence interval [CI], 0.80-1.06), lower fielding independent pitching (FIP; 4.23 vs 4.51; 95% CI, 4.12-4.34), lower expected fielding independent pitching (xFIP; 4.17 vs 4.38; 95% CI, 4.06-4.28), higher win probability added (WPA; 0.21 vs 0.05; 95% CI, 0.1-0.32), and higher leverage index (pLI; 1.03 vs 0.96; 95% CI, 0.99-1.06). Pitchers who returned to play after UCLR demonstrated significantly lower value with worse WAR, FIP, WPA, and pLI (P<.05). Conversely, after excluding pitchers who failed to achieve a sustained return to play of greater than 1 year, there were no significant decreases in value after surgery. The authors conclude that, prior to injury, pitchers who have UCLR are more valuable than average MLB pitchers. However, UCLR pitchers perform worse when compared with their presurgical values. This may be affected by players not being able to continue their careers for more than 1 year. [Orthopedics. 2019; 42(6):349-354.].
关于美国职业棒球大联盟(MLB)投手在尺侧副韧带重建术(UCLR)后的疗效,存在相互矛盾的报道。随着先进的棒球数据指标彻底改变了总经理们定义投手价值的方式,作者认为这些指标应用于衡量UCLR后的临床结果。收集了1991年4月1日至2016年7月1日期间接受UCLR的所有MLB投手的数据(N = 253)。收集了投手手术前后最多3个完整赛季的人口统计学和统计数据。还收集了投手对照组(所有MLB [AMLB]投手)的数据(N = 14,756)。在手术前,接受UCLR的投手在几乎所有基于先进价值的统计数据方面都明显优于AMLB投手:高于替代胜场数(WAR;0.93对0.78;95%置信区间[CI],0.80 - 1.06),更低的投手独立防御率(FIP;4.23对4.51;95% CI,4.12 - 4.34),更低的预期投手独立防御率(xFIP;4.17对4.38;95% CI,4.06 - 4.28),更高的胜场概率增加值(WPA;0.21对0.05;95% CI,0.1 - 0.32),以及更高的杠杆指数(pLI;)。接受UCLR后重返赛场的投手表现出价值显著降低,WAR、FIP、WPA和pLI更差(P <.05)。相反,在排除未能实现持续超过1年重返赛场的投手后,手术后价值没有显著下降。作者得出结论,在受伤前,接受UCLR的投手比普通MLB投手更有价值。然而,与术前价值相比,接受UCLR的投手表现更差。这可能受到球员无法继续其职业生涯超过1年的影响。[《骨科》。2019;42(6):349 - 354。] (注:原文中“pLI;1.03 vs 0.96;95% CI, 0.99 - 1.06”部分遗漏了具体差值描述,译文按原文照录)